LYN-1604
目录号 : KCM12492 CAS No. : 2088939-99-3 纯度 : ≥98%

LYN-1604 是一种有效的 UNC-51 样激酶 1 (ULK1) 激活剂,EC50 值为 18.94 nM。LYN-1604 可用于三阴性乳腺癌 (TNBC) 的研究。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO
In-stock
1mg
In-stock
5mg
In-stock
10mg
In-stock
25mg
In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC).

IC50&Target

ULK1

18.94 nM (EC50)

体外研究

LYN-1604 is a potential ULK1 agonist (enzymatic activity=195.7% at 100 nM and IC50=1.66 μM against MDA-MB-231 cells).
LYN-1604 binds to wild-type ULK1 with a binding affinity in the nanomole range (KD=291.4 nM) .
LYN-1604 (0.5, 1.0 and 2.0 μM) induces cell death via the ULK complex in MDA-MB-231 cells.
LYN-1604 (0.5-2 μM, 24 hours) induces remarkable up-regulation of Beclin-1 and degradation of p62, as well as transformation of LC3-I to LC3-II in MDA-MB-231 cells.
LYN-1604 induces ATG5-dependent autophagy via the ULK complex.
LYN-1604 can also increase cleavage of caspase3 and induce apoptosis.

 

Cell Viability Assay

Cell Line: MDA-MB-231 cells
Concentration: 0.5, 1.0 and 2.0 μM
Incubation Time:  
Result: Induced cell death. Autophagy ratio was increased in a dose-dependent manner.

Western Blot Analysis

Cell Line: MDA-MB-231 cells
Concentration: 0, 0.5, 1, and 2 μM
Incubation Time: 24 hours
Result: Induced remarkable up-regulation of Beclin-1 and degradation of p62, as well as transformation of LC3-I to LC3-II.
体内研究

LYN-1604 (low dose, 25 mg/kg; median dose, 50 mg/kg; high dose, 100 mg/kg; intragastric administration once a day for 14 days) inhibits the growth of xenograft TNBC by targeting ULK1-modulated cell death.

 

Animal Model: 24 female nude mice (BALB/c, 6-8 weeks, 20-22 g)
Dosage: Low dose, 25 mg/kg; median dose, 50 mg/kg; high dose, 100 mg/kg
Administration: Intragastric administration; once a day for 14 days
Result: Significantly inhibited the growth of xenograft MDA-MB-231 cells. The body weights of mice were stable. By the end of the experiment, the liver and spleen weight indexes of mice were slightly increased in parts of the groups, while the kidney weight index was not affected in all dose groups.
 
分子式
C33H43Cl2N3O2
分子量
584.62
CAS号
2088939-99-3
中文名称
2-[双(2-甲基丙基)氨基]-1-[4-[2-(2,4-二氯苯基)-2-(2-萘基甲氧基)乙基]-1-哌嗪基]乙酮
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶解性数据
In Vitro: 

DMSO: 100 mg/mL (171.05 mM; Need ultrasonic)

配制储备液
                                           
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
                                                                                                                    
1 mM 1.7105 mL 8.5526 mL 17.1051 mL
5 mM 0.3421 mL 1.7105 mL 3.4210 mL
10 mM 0.1711 mL 0.8553 mL 1.7105 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

配置后的溶液总体积:

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。